期刊文献+

纳米技术在口服难溶性药物的研究进展 被引量:8

下载PDF
导出
摘要 据报道,有〉70%的化学合成药物存在难溶性问题[1],约40%的新化学实体(NCEs)因其难溶性而无法进入临床试验,使其应用受到很大程度的限制[2]。口服给药不仅方便且患者顺应性高,是新药首选的给药途径之一。但对于生物药剂学分类系统中的第Ⅱ类药物(即穿膜性好,但溶解度低而言,因在胃肠道中溶解度低或溶出速率慢,可能导致口服生物利用度低。因此,解决因药物难溶性引起的口服低吸收问题,可提高这类药物的口服生物利用度。解决药物难溶性主要有两条途径:①提高溶解度,增加药物溶出:提高难溶性药物溶解度或溶出速率的常用方法有成盐、改变药物晶型、使用增溶剂或减小粒径等;②应用纳米给药系统,将药物包入载体内部,使药物以载药传递体形式被肠道吸收。
出处 《中南药学》 CAS 2013年第5期362-365,398,共5页 Central South Pharmacy
  • 相关文献

参考文献24

  • 1Rupp CH,Steckel Muller BW.Solubilization of poorly water-soluble drugs by mixed micelles based on hydrogenated phosphati-dylcholine[J].Int J Pharm,2010,395(12):272-280.
  • 2Merisko-Liversidge EM,Liversidge GG.Drug nanoparticles:formulating poorly water-soluble compounds[J].Toxicol Pathol,2008,36(1):43-48.
  • 3胡宏伟,李剑勇,吴培星,周绪正,张继瑜.纳米乳在药剂学中的研究进展及其应用[J].湖北农业科学,2009,48(3):747-750. 被引量:25
  • 4Muller RH,Radtke M,Wissing SA.Nanostructured lipid mat-rices for improved microencapsulation of drugs[J].Int J Pharm,2002,242(12):121-128.
  • 5Liu Y,Zhang P,Zhang X,et al.Optimization and in situ intes-tinal absorption of self-microemulsifying drug delivery system oforidonin[J].Int J Pharm,2009,365(12):136-142.
  • 6Ragelle H,Mancietet SC,Seguin J,et al.Nanoemulsion formu-lation of fisetin improves bioavailability and antitumour activity inmice[J].Int J Pharm,2012,427(2):452-459.
  • 7Tiwari R,Pathak K.Nanostructured lipid carrier versus solid lipidnanoparticles of simvastatin:Comparative analysis of characteris-tics,pharmacokinetics and tissue uptake[J].Int J Pharm,2011,415(12):232-243.
  • 8Tian QP,Ren FD,Xu Z,et al.Preparation of high solubilizablemicroemulsion of naproxen and its solubilization mechanism[J].Int J Pharm,2012,426(12):202-210.
  • 9Fang JY,Fang CL,Liu CH,et al.Lipid nanoparticles as vehic-les for topical psoralen delivery:Solid lipid nanoparticles(SLN)versus nanostructured lipid carriers(NLC)[J].Eur J Pharm Bio-pharm,2008,70:633-640.
  • 10Chen CC,Tsai TH,Huang ZR,et al.Effects of lipophilic emul-sifiers on the oral administration of lovastatin from nanostructuredlipid carriers:Physicochemical characterization and pharmacoki-netics[J].Eur J Pharm Biopharm,2010,74(3):474-482.

二级参考文献23

  • 1姚静,周建平,杨宇欣,平其能.微乳对难溶性药物增溶机理的研究[J].中国药科大学学报,2004,35(6):495-498. 被引量:28
  • 2孙红武,欧阳五庆.黄连素口服纳米乳的研制、质量及安全性评价[J].上海交通大学学报(农业科学版),2007,25(1):60-65. 被引量:16
  • 3余东升,姚昶,潘立群.黄芪注射液浓缩液微乳的制备及其体外释放实验评价研究[J].山东中医药大学学报,2007,31(2):148-151. 被引量:17
  • 4杜红,牛欣,冯前进,叶明磊.穿心莲内酯口服微乳与穿心莲内酯片在家兔体内生物利用度的比较研究[J].中药新药与临床药理,2007,18(3):217-219. 被引量:18
  • 5DANIELSSON I,LINDMAN B. The definition of a microemulsion[J]. Colloids and Surf aces,1981,3:391.
  • 6EROL Y, HANS-HUBERT B. Design of a phytosphingosine- containing, positively -charged nanoemulsion as a colloidal carrier system for dermal application of ceramides [J]. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60: 91-98.
  • 7ADWOA O,NORNOO, DIANA S L C. Cremophor-free intravenous microemulsions for paclitaxel Ⅱ. Stability, in vitro release and pharmacokinetics[J]. International Journal of Pharmaceutics , 2008, 349: 117-123.
  • 8THEVERIN M A,GROSSIORD J L,POELMAN M C. Sucrose esters/cosurfactant microemulsion systems for transdermal delivery: assessment of bicontinous structures[J]. Int J Pharm, 1996,137 : 177-186.
  • 9TIMOTHY E .MOREY. Activity of Microemulsion-based Nanoparticles at the Human Bio-Nano Interfeese: Concentration-Dependent Effects on Thrombosis andHemolysis in Whole Blood [J]. Journal of Nanoparticle Research,2004,6(2):159-170.
  • 10YASUSHIGEMOR,I YASUHIROOKASTU, YUKITSUJIM-OTO, et al.Titanium Dioxide. Nanoparticles Produced in Water- in- Oil Emulsion [J]. Journal of Nanoparticle Research,2001,3: 219.

共引文献24

同被引文献93

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部